glp-1 ibd Pharmacological interventions for obesity in patients with inflammatory bowel disease: A systematic review of receptor agonist efficacy and safety GLP-1 Medications: Everything You Need

Their study appeared in Science Translational Medicine

Trial: Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial

Malakootian M, Soveizi M, Gholipour A, Oveisee M

Second Nature is a single provider for both medication and behavioural support

or A BMI of 27 or higher with at least one weight-related condition, such as high blood pressure or high cholesterol

[1] [2] Clinical studies suggest that tirzepatide may reduce energy intake, though the extent varies among individuals and tends to be most notable during initial therapy